Cyclophosphamide and Vitreous floaters - a phase IV clinical study of FDA data

Summary:

Vitreous floaters is found among people who take Cyclophosphamide, especially for people who are female, 60+ old, have been taking the drug for < 1 month.

The phase IV clinical study analyzes which people take Cyclophosphamide and have Vitreous floaters. It is created by eHealthMe based on reports of 149,447 people who have side effects when taking Cyclophosphamide from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.

On Feb, 03, 2023

149,447 people reported to have side effects when taking Cyclophosphamide.
Among them, 48 people (0.03%) have Vitreous floaters.

What is Cyclophosphamide?

Cyclophosphamide has active ingredients of cyclophosphamide. It is often used in multiple myeloma. eHealthMe is studying from 149,590 Cyclophosphamide users for its effectiveness, alternative drugs and more.

What is Vitreous floaters?

Vitreous floaters (spots before the eyes) is found to be associated with 1,437 drugs and 799 conditions by eHealthMe.

Number of Cyclophosphamide and Vitreous floaters reports submitted per year:

Could Cyclophosphamide cause Vitreous floaters?

Time on Cyclophosphamide when people have Vitreous floaters *:

Gender of people who have Vitreous floaters when taking Cyclophosphamide *:

female: 68.09 %
male: 31.91 %

Age of people who have Vitreous floaters when taking Cyclophosphamide *:

Common drugs people take besides Cyclophosphamide *:

Common side effects people have besides Vitreous floaters *:

Visual Acuity Reduced (reduced clearness of vision): 24 people, 50.00%
Pain: 18 people, 37.50%
Stress And Anxiety: 16 people, 33.33%
Osteonecrosis Of Jaw (death of bone of jaw): 15 people, 31.25%
Fall: 14 people, 29.17%
Osteomyelitis (infection of bone): 14 people, 29.17%
Rashes (redness): 14 people, 29.17%
Sinusitis (inflammation of sinus): 13 people, 27.08%
Weakness: 13 people, 27.08%
Fever: 12 people, 25.00%

Common conditions people have *:

Acute Lymphocytic Leukemia (All) (cancer of the white blood cells characterized by excess lymphoblasts): 6 people, 12.50%
Acute Myeloid Leukaemia (acute cancer in which the bone marrow makes abnormal myeloblasts): 4 people, 8.33%
Bone Marrow Conditioning Regimen: 4 people, 8.33%
High Blood Pressure: 4 people, 8.33%
Fusarium Infection (fungal infection): 3 people, 6.25%
Vasculitis (inflammation of a blood vessel or blood vessels): 2 people, 4.17%
Gastric Ulcer (stomach ulcer): 2 people, 4.17%
Acute Graft Versus Host Disease In Skin (acute complication on skin following an allogeneic tissue/blood transplant): 2 people, 4.17%
Allergic Rhinitis: 2 people, 4.17%
Asthma: 2 people, 4.17%

* Approximation only. Some reports may have incomplete information.

Do you take Cyclophosphamide and have Vitreous floaters?

Check whether Vitreous floaters is associated with a drug or a condition

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.

Related publications that referenced our studies

Hu P, Lu L, Hu B, Deng F, Fei WJ, "Cyclophosphamide‐Induced Hypertensive Encephalopathy in a Young Girl With Lupus", The Journal of Clinical Hypertension, 2012 Apr .

Related studies

How severe was Vitreous floaters and when was it recovered:

Vitreous floaters in Cyclophosphamide

Expand to all the drugs that have ingredients of cyclophosphamide:

Vitreous floaters and drugs with ingredients of cyclophosphamide (71 reports)

Alternative drugs to, pros and cons of Cyclophosphamide:

Cyclophosphamide (149,590 reports)

Common Cyclophosphamide side effects:

Browse all side effects of Cyclophosphamide:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Vitreous floaters treatments and more:

Vitreous floaters (9,379 reports)

COVID vaccines that are related to Vitreous floaters:

Common drugs associated with Vitreous floaters:

How the study uses the data?

The study uses data from the FDA. It is based on cyclophosphamide (the active ingredients of Cyclophosphamide) and Cyclophosphamide (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.